Clinical Characteristics of Motor Functional Neurological Disorder Manifesting As Limb Weakness After Vaccination Against Coronavirus Disease 2019: A Case Series

Overview

Journal eNeurologicalSci

Specialty Neurology

Date 2023 Dec 4

PMID 38046447

Authors

Masayuki Ohira

Takashi Osada

Hiroaki Kimura

Terunori Sano

Masaki Takao

Affiliations

Soon will be listed here.

Abstract

Background: The characteristics of functional limb weakness (FLW) as one of the manifestations of functional neurological disorder after vaccination against coronavirus disease 2019 (COVID-19) remain controversial.

Methods: In this descriptive case series, we aimed to elucidate the characteristics of Japanese patients with FLW who claimed muscle weakness after COVID-19 vaccination among patients who visited our outpatient clinic between 1 June 2021 and 31 December 2022.

Results: Nine patients were diagnosed with FLW (mean age: 30.8 years), including two men and seven women. Seven patients were vaccinated with the BioNTech/Pfizer vaccine and two with the mRNA-1273 Moderna vaccine. All patients demonstrated various positive signs for FLW. Magnetic resonance imaging or computed tomography indicated no abnormality that could explain their symptoms. At the time of the clinic visit, five patients were treated for psychiatric disorders, including depression, insomnia, attention-deficit hyperactivity disorder, and Asperger's syndrome. Muscle weakness spread to the limbs beyond the vaccinated arm in seven patients.

Conclusions: We describe the basic characteristics of FLW in Japanese patients after COVID-19 vaccination. Further recognition of these characteristics could aid the diagnosis of FLW by physicians allowing them to support these patients effectively.

References

Kadali R, Janagama R, Peruru S, Malayala S . Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers. Int J Infect Dis. 2021; 106:376-381. PMC: 8049195. DOI: 10.1016/j.ijid.2021.04.047. View

Ohira M, Sano T, Takao M . Clinical features of patients who visited the outpatient clinic for long COVID in Japan. eNeurologicalSci. 2022; 28:100418. PMC: 9335519. DOI: 10.1016/j.ensci.2022.100418. View

Espay A, Aybek S, Carson A, Edwards M, Goldstein L, Hallett M . Current Concepts in Diagnosis and Treatment of Functional Neurological Disorders. JAMA Neurol. 2018; 75(9):1132-1141. PMC: 7293766. DOI: 10.1001/jamaneurol.2018.1264. View

Harris S . Psychogenic movement disorders in children and adolescents: an update. Eur J Pediatr. 2019; 178(4):581-585. DOI: 10.1007/s00431-019-03317-8. View

Luiz Marchetti R, Gallucci-Neto J, Kurcgant D, Proenca I, Valiengo L, Fiore L . Immunization stress-related responses presenting as psychogenic non-epileptic seizures following HPV vaccination in Rio Branco, Brazil. Vaccine. 2020; 38(43):6714-6720. DOI: 10.1016/j.vaccine.2020.08.044. View

Hallett M, Aybek S, Dworetzky B, McWhirter L, Staab J, Stone J . Functional neurological disorder: new subtypes and shared mechanisms. Lancet Neurol. 2022; 21(6):537-550. PMC: 9107510. DOI: 10.1016/S1474-4422(21)00422-1. View

Saxena A, Godena E, Maggio J, Perez D . Towards an Outpatient Model of Care for Motor Functional Neurological Disorders: A Neuropsychiatric Perspective. Neuropsychiatr Dis Treat. 2020; 16:2119-2134. PMC: 7509337. DOI: 10.2147/NDT.S247119. View

Kadali R, Janagama R, Peruru S, Gajula V, Madathala R, Chennaiahgari N . Non-life-threatening adverse effects with COVID-19 mRNA-1273 vaccine: A randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms. J Med Virol. 2021; 93(7):4420-4429. PMC: 8250701. DOI: 10.1002/jmv.26996. View

Grana C, Ghosn L, Evrenoglou T, Jarde A, Minozzi S, Bergman H . Efficacy and safety of COVID-19 vaccines. Cochrane Database Syst Rev. 2022; 12:CD015477. PMC: 9726273. DOI: 10.1002/14651858.CD015477. View

10.

Lim N, Wood N, Prasad A, Waters K, Singh-Grewal D, Dale R . COVID-19 Vaccination in Young People with Functional Neurological Disorder: A Case-Control Study. Vaccines (Basel). 2022; 10(12). PMC: 9782633. DOI: 10.3390/vaccines10122031. View

11.

Chouksey A, Pandey S . Functional Movement Disorders in Elderly. Tremor Other Hyperkinet Mov (N Y). 2019; 9. PMC: 6691911. DOI: 10.7916/tohm.v0.691. View

12.

Ercoli T, Lutzoni L, Orofino G, Muroni A, Defazio G . Functional neurological disorder after COVID-19 vaccination. Neurol Sci. 2021; 42(10):3989-3990. PMC: 8319586. DOI: 10.1007/s10072-021-05504-8. View

13.

Lucia V, Kelekar A, Afonso N . COVID-19 vaccine hesitancy among medical students. J Public Health (Oxf). 2020; 43(3):445-449. PMC: 7799040. DOI: 10.1093/pubmed/fdaa230. View

14.

Carson A, Lehn A . Epidemiology. Handb Clin Neurol. 2016; 139:47-60. DOI: 10.1016/B978-0-12-801772-2.00005-9. View

15.

Goldstein L, Robinson E, Reuber M, Chalder T, Callaghan H, Eastwood C . Characteristics of 698 patients with dissociative seizures: A UK multicenter study. Epilepsia. 2019; 60(11):2182-2193. PMC: 6899659. DOI: 10.1111/epi.16350. View

16.

Cuykx M, Mortele O, Jansens H, Schouwers S, Meskal A, Hoffbauer I . Serological response in health care workers after a single dose of SARS-CoV-2 vaccine using six automated SARS-CoV-2 antibody assays. Diagn Microbiol Infect Dis. 2021; 101(2):115486. PMC: 8272050. DOI: 10.1016/j.diagmicrobio.2021.115486. View

17.

Chapin-Bardales J, Gee J, Myers T . Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines. JAMA. 2021; 325(21):2201-2202. DOI: 10.1001/jama.2021.5374. View

18.

Parimi K, Gilkeson K, Creamer B . COVID-19 vaccine hesitancy: Considerations for reluctance and improving vaccine uptake. Hum Vaccin Immunother. 2022; 18(5):2062972. PMC: 9897654. DOI: 10.1080/21645515.2022.2062972. View

19.

Lin C, Peng C, Liu H, Chiu N . Psychogenic movement disorder after H1N1 influenza vaccination. J Neuropsychiatry Clin Neurosci. 2011; 23(3):E37-8. DOI: 10.1176/jnp.23.3.jnpe37. View

20.

Finsterer J . Neurological Adverse Reactions to SARS-CoV-2 Vaccines. Clin Psychopharmacol Neurosci. 2023; 21(2):222-239. PMC: 10157009. DOI: 10.9758/cpn.2023.21.2.222. View